Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
(ABEO) MC $23 m -BIG Phase 3 results expected in the coming ...Shares Out 6 million
"Topline data from the Phase 3 VIITAL™ study of EB-101 in RDEB is on track for late third quarter to early fourth quarter of 2022 "
EYEN $1.96 up 22% ---BIG Phase 3 readout coming within days
(ARDS) $1.46 --has 2x Big Phase 3 Drugs and low valuation of $26 million ,this could be the next big runner like RVPH
Continued enrollment in the Company's Phase 3 study evaluating AR-301 for the treatment of Ventilator Associated Pneumonia (VAP). Aridis remains on track to report top-line data from this study in 2H 2022.
EYEN,RVPH & ABEO all Phase 3 gems , EYEN & ABEO about to release Phase 3 data in September while RVPH expected in mid 2023 ...EYEN looks more attractive at this time with 3x Phase 3 Products
ABEO $4.25 .big Phase 3 data around the corner
(ABEO) MC $24 million ....O/S 6 mil ...
"Topline data from the Phase 3 VIITAL™ study of EB-101 in RDEB is on track for late third quarter to early fourth quarter of 2022 "
ABEO $4.25 next to explode like NERV with big Phase 3 data around the corner
(ABEO) MC $24 million ....O/S 6 mil ...
"Topline data from the Phase 3 VIITAL™ study of EB-101 in RDEB is on track for late third quarter to early fourth quarter of 2022 "
(ABEO) MC $24 m / O/S 6 mil / Phase 3 results in September
"Topline data from the Phase 3 VIITAL™ study of EB-101 in RDEB is on track for late third quarter to early fourth quarter of 2022 "
(VAXX) $2.45 --Best Covid Vaccine ? Company about to release Phase 3 results if positive then stock could be a multibagger
"The Phase 3 heterologous boost study evaluating UB-612 against COVID-19 in subjects who have received primary immunization from mRNA, adenovirus vector, or inactivated viral vaccines is ongoing. Vaxxinity expects a topline readout in the second half of 2022, and if successful, these data will support global marketing authorization applications."
Vaxxinity looks to pioneer the next revolution in pharma
https://www.pharmavoice.com/news/vaxxinity-to-pioneer-the-next-revolution/617229/
RVPH not RVPX
(EDRY) $17 --PE 1 --Float 300k shares--MC $54 million --Book Value $34.50 per share
(APTX) 0.63 Halted -likely to release Phase 2b results lets hope for positive outcome
$COHN now $13 there are only 600k shrs on ther float with volume this one likely going parabolic
(COHN) $11.90 --Float 600k --MC $20 million --Book Value $35 per share ..maybe next MEGL here which went from $10 to $200+ within days
(COHN) $11.90 --Float 600k --MC $20 million --Book Value $35 per share
(COHN) $11.80 --Float 600k --MC $20 million --Book Value $35 per share = next HKD ???
APTX $0.60-- Cash $1.40 per Shr + 3x Big Drugs in Phase 2 with first readout expected during August
"Company expects to report results from Phase 2b study of NYX-2925 in fibromyalgia in August"
(COHN) $11.80..Float 600k --MC $20 m = next HKD ??
(COHN) $11.80..Float 600k --MC $20 m = next MEGL ??
(RVPH) $0.66 trading under cash + Potential Blockbuster nearing Phase 3 readout. has very low valuation of just $10 million
https://revivapharma.com/wp-content/uploads/2015/03/Pipeline_01.png
(APTX) $0.53..Cash $1.40 per shr --Data readout IMMINENT
Company expects to report results from Phase 2b study of NYX-2925 in fibromyalgia in August
Data from Phase 2 study of NYX-458 in cognitive impairment expected in 1Q 2023
IND cleared for NIH grant-funded evaluation of NYX-783 in opioid use disorder
$85 million cash balance provides operational runway into 2024 and enables readouts from multiple Phase 2 studies
(CING) $1.55..low floater about to Breakout ..clinical data coming next week
(SPRC) MC $8 mil- low floater with MEGA Pipeline targeting multi billion dollar markets
https://s.yimg.com/uu/api/res/1.2/KPVkf9nPgETriDOtaIIynA--~B/aD02NTQ7dz0xMjEyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/5f3749bb3d8b467bfb8040e2c83d9e68">https://s.yimg.com/uu/api/res/1.2/KPVkf9nPgETriDOtaIIynA--~B/aD02NTQ7dz0xMjEyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/5f3749bb3d8b467bfb8040e2c83d9e68" />
(APTX) $0.47 --Cash $1.48 per shr --important data readout in the coming days
Aptinyx continues to believe that NYX-2925 can offer a novel therapeutic approach for fibromyalgia. To this end, the company plans to report data from ongoing fibromyalgia phase 2b study in early to mid third quarter.
(APTX) $0.47 --Cash $1.48 per shr --important data readout in the coming days
Aptinyx continues to believe that NYX-2925 can offer a novel therapeutic approach for fibromyalgia. To this end, the company plans to report data from ongoing fibromyalgia phase 2b study in early to mid third quarter.
(ADIL) $1.85 --BIG Ph 3 data tomorrow ---Market cap $47 million ..maybe a good opp to make some quick profit
Adial Pharmaceuticals to Announce Topline Results of ONWARD™ Phase 3 Trial for AD04 in Patients With Alcohol Use Disorder
https://finance.yahoo.com/news/adial-pharmaceuticals-announce-topline-results-132500273.html
today announced that it plans to report topline results from the Company’s ONWARD™ Phase 3 clinical trial on Wednesday, July 20, 2022.